On September 17, 2026, Charles River Laboratories International Inc CRL shares rose 3.0% to $281.67, narrowing the stock's performance in a 52-week range of $144.26 to $303.31. This recent uptick comes amid a year-to-date increase of 41.2% and an impressive 84.4% rise over the past year.
- GF Value™ verdict: Current price of $281.67 is 45.0% above the GF Value™ estimate of $194.22.
- GF Score™ is 69/100, indicating an above-average performance relative to its peers.
- Notable signal: Over the past 12 months, insiders sold $42.6 million worth of shares with no purchases, indicating a net selling trend.
Is CRL Overvalued or Undervalued?
The current price of Charles River Laboratories at $281.67 is significantly above its GF Value™ estimate of $194.22, suggesting that the stock is overvalued by 45.0%. GF Value™ is GuruFocus' proprietary intrinsic value estimate, which considers historical trading multiples, past business growth, and future performance estimates. For a company like CRL, which has been unprofitable and cash flow negative, relying on earnings-based valuation metrics such as P/E may not provide a reliable assessment of its true worth.
Given the GF Valuation label of "Sign...